Please note some content on this site is no longer supported on Internet Explorer 8, we recommend you upgrade your browser
Targovax is a clinical stage immuno-oncology company dedicated to the development of highly targeted immunotherapy treatments for cancer patients.
Targovax is developing two complementary and highly targeted approaches to cancer immunotherapy:
Both treatment approaches harness the patient’s own immune system to fight the cancer.
Targovax is committed to the design and development of highly targeted immunotherapy for patients with RAS-mutated cancers – an area of high unmet medical need with few and limited treatment options – and for patients with difficult to treat solid tumors.
The Targovax pipeline, built on a robust knowledge of the immunotherapy area and unique technologies, includes a number of product candidates targeted at a wide range of cancer types. Its lead candidates, TG01 and ONCOS-102 have successfully completed Phase I clinical trials and are either now in Phase I/II (TG01) or soon to start trials (ONCOS-102)
Read more about ONCOS-102
Read more about TG01, TG02 & TG03
One of Targovax's therapeutic approaches is a peptide-based immunotherapy targeting mutations in the RAS genes associated with cancer. Mutation of RAS disrupts normal cell division signalling, and occurs early in the transformation from a normal to a cancer cell.
RAS mutations are a key driver of cancer progression and treatment resistance. They are found in 20 - 30% of all cancers1, over 85% of pancreatic cancers2, 50% of colorectal cancers3, between 20 and 30% of non small cell lung cancers4 and between 20 and 30% of malignant melanomas1.
Few treatment options are available for patients with RAS mutations and of limited efficacy, highlighting the significant unmet medical need for these patients.
Targovax is also developing a virus-based immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumors.
This cancer immunotherapeutic technology has a targeted mechanism of action making tumors visible to the immune system and educating the immune system to recognize and attack patient specific tumor cells. The technology is based on adenoviruses engineered to kill tumor cells primarily via activation of a systemic, patient-targeted anti-tumor immune response.
Targovax owns a patent portfolio protecting its pipeline with patents and patent applications from different patent families covering its products, expiring from 2029.
Orphan Drug Designation (ODD) has been granted in the EU and the US for TG01 for pancreatic cancer, and for ONCOS-102 for the indications of mesothelioma, soft tissue sarcoma and ovarian cancer.
ODD ensures 10 and 7 years of market protection in the EU and in the US, respectively, from the date of market approval.
Investor Email Alerts